Group 1 - The stock price of Qianhong Biopharma fell by 2.05% on September 19, closing at 9.54 CNY per share, with a trading volume of 142 million CNY and a turnover rate of 1.56%, resulting in a total market capitalization of 12.209 billion CNY [1] - Year-to-date, Qianhong Biopharma's stock price has increased by 56.83%, but it has seen a decline of 5.36% over the last five trading days and 12.48% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on August 7, where it recorded a net purchase of 10.2288 million CNY [1] Group 2 - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province, and specializes in the production and sales of various pharmaceutical products, including lyophilized powder and injections [2] - The company's main business revenue composition includes 62.97% from formulations and 36.70% from raw materials, with other sources contributing 0.33% [2] - As of June 30, 2025, Qianhong Biopharma reported a revenue of 862 million CNY, a year-on-year increase of 0.72%, and a net profit attributable to shareholders of 258 million CNY, reflecting a growth of 41.17% [2] Group 3 - Since its A-share listing, Qianhong Biopharma has distributed a total of 1.862 billion CNY in dividends, with 453 million CNY distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 29.1651 million shares, a decrease of 11.9864 million shares from the previous period [3]

Group 1 - The company has completed the review of its generic drug, Hydrobromide Sitagliptin Tablets, on September 12, but has not issued any announcement regarding this progress [1] - The company faced scrutiny due to a regulatory letter received for the illegal increase in shares by the actual controller's concerted actors, highlighting issues with information disclosure [1] - The company responded on September 17, stating that the generic drug is still undergoing supplementary pharmaceutical data review and has not yet completed the review process, assuring compliance with regulatory disclosure obligations [1]

Core Viewpoint - Qianhong Pharmaceutical (002550.SZ) received a warning letter from the Jiangsu Regulatory Bureau of the China Securities Regulatory Commission regarding a violation of disclosure regulations related to shareholding changes by Wang Ke [1] Summary by Relevant Sections - **Incident Details** - On June 11, 2025, Wang Ke increased his stake in Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. by acquiring 9.6 million shares through block trading, amounting to 84.096 million yuan [1] - Following this transaction, the combined shareholding percentage of Wang Ke and his concerted action partner Wang Yaofang rose from 24.91% to 25.66% [1] - **Regulatory Findings** - Wang Ke failed to timely disclose the increase in shareholding when it reached the 25% threshold and only reported it on June 20, 2025, through a detailed equity change report and a notice regarding the change in concerted action rights [1] - This behavior was found to violate Article 13, Paragraphs 1 and 2 of the "Measures for the Administration of the Acquisition of Listed Companies" (CSRC Order No. 227) [1] - **Consequences** - The Jiangsu Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure, which will be recorded in the securities and futures market integrity file [1] - Wang Ke is required to reflect on this incident, enhance his understanding of securities laws and regulations, and submit a written report to the bureau within 10 working days from the receipt of the decision [1]

Core Viewpoint - The company, Qianhong Biopharmaceutical (002550.SZ), received a warning letter from the Jiangsu Regulatory Bureau of the China Securities Regulatory Commission regarding a violation of disclosure regulations related to shareholding changes [1] Group 1: Regulatory Actions - The warning was issued to Wang Ke for failing to timely disclose an increase in shareholding through a block trade on June 11, 2025, where he acquired 9.6 million shares for a total of 84.096 million yuan [1] - Following this transaction, the combined shareholding of Wang Ke and his concerted action partner, Wang Yaofang, increased from 24.91% to 25.66% [1] - The violation pertains to the failure to disclose the shareholding change when it crossed the 25% threshold, with the required disclosure only made on June 20, 2025 [1] Group 2: Compliance and Recommendations - The regulatory body emphasized the need for Wang Ke to learn from this incident, strengthen knowledge of securities laws, and adhere to information disclosure obligations [1] - Wang Ke is required to submit a written report to the regulatory authority within 10 working days from the receipt of the warning letter [1]

Group 1 - Shareholder Wang Ke increased his stake in the company by acquiring 9.6 million shares through block trading, with a transaction amount of 84.096 million yuan [1] - The combined shareholding ratio of Wang Ke and his concerted party Wang Yaofang rose from 24.91% to 25.66% [1] - Jiangsu Securities Regulatory Bureau issued a warning letter to Wang Ke on September 11, 2025, for failing to disclose timely when his shareholding ratio approached the 25% threshold [1]

本公司及董事会全体成员保证信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：002550 证券简称：千红制药 公告编号：2025-027 常州千红生化制药股份有限公司 关于收到江苏证监局对公司股东出具警示函的公告 二、相关情况说明 公司及股东等相关责任人收到《警示函》后高度重视，将严格按照江苏证监 局的要求，深入反思，充分汲取教训并引以为戒，切实加强对《上市公司信息披 露管理办法》及相关法律法规、规范性文件的学习，切实提高规范意识和履职能 力，提升公司规范运作水平和信息披露质量，杜绝此类事件再次发生，并将严格 按照江苏证监局的要求及时报送书面报告。 本次收到《警示函》事项不会影响公司正常的生产经营，公司将严格按照相 关监管要求和有关法律法规的规定，及时履行信息披露义务，敬请广大投资者注 意投资风险。 特此公告。 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）于 2025 年 9 月 11 日收到中国证券监督管理委员会江苏监管局出具的《关于对王轲采取 出具警示函措施的决定》（〔2025〕154 号）（以下简称"警示函"），现将相 关内容公告如下： 一、警示函的主要内 ...

Group 1 - The company Qianhong Pharmaceutical (002550.SZ) has completed Phase II clinical trials for its innovative drug QHRD106 and has submitted the relevant materials to the CDE for review, with plans to enter Phase III clinical trials upon approval [1] - QHRD107 has completed patient enrollment for Phase IIa and is actively engaging in critical clinical communication with the CDE to advance its clinical research [1] - The company encourages investors to pay attention to future announcements for specific progress updates [1]

Core Viewpoint - The company is addressing concerns regarding potential disagreements between major shareholders affecting the progress of clinical trials for two innovative drugs, QHRD106 and QHRD107, and reassures that these projects are advancing as planned [2]. Group 1 - The company confirmed that its board and management are committed to promoting innovation and development [2]. - The clinical trials for the innovative drug projects QHRD106 and QHRD107 are proceeding in an orderly manner as scheduled [2]. - The company is currently in active communication with regulatory authorities to apply for the next phase of clinical research [2].

Group 1 - The Chinese government will include the HPV vaccine in the national immunization program, aiming to protect women's health and potentially eliminate cervical cancer by 2050 [1] - The inclusion of the HPV vaccine is expected to provide significant cost-effectiveness in preventing cervical cancer among adolescent females [1] Group 2 - Reports indicate that the Trump administration may consider an executive order to impose stricter restrictions on experimental drugs and clinical data from China, which has led to a decline in the stock prices of innovative drug companies in A-shares and H-shares [2] - However, some institutions believe that these restrictions may be mere posturing, as the development of Chinese innovative drugs continues to accelerate, with improvements in pipeline quantity and quality [2] Group 3 - Wang Chen has been removed from his position as Vice President of the Chinese Academy of Engineering, with the reasons for his dismissal remaining unclear [3] - Wang Chen is a prominent expert in respiratory medicine and has been involved in significant medical projects, which have previously sparked controversy [3] Group 4 - Zhang Jianhui, the General Manager of Jindike, passed away due to illness, marking a significant loss for the company and highlighting the risks associated with reliance on key individuals in the biotech sector [4] Group 5 - Qianhong Pharmaceutical received a regulatory letter due to its actual controller's failure to comply with disclosure obligations after increasing shareholding beyond the stipulated threshold [5] - The incident reflects potential internal control weaknesses within Qianhong Pharmaceutical [5]

Group 1 - The Chinese government will include the HPV vaccine in the national immunization program, aiming to protect women's health and potentially eliminate cervical cancer by 2050 [1] - The introduction of HPV vaccination for adolescent girls is expected to be cost-effective in preventing cervical cancer [1] Group 2 - Reports indicate that the Trump administration may consider an executive order to restrict experimental drugs and clinical data from China, which has led to a decline in the A-share and H-share innovative drug sectors [2] - Some institutions believe that the proposed restrictions may be mere posturing, as China's innovative drug development continues to progress significantly [2] - The potential executive order could create higher barriers for licensing agreements between Chinese pharmaceutical companies and large U.S. pharmaceutical firms if implemented [2] Group 3 - Wang Chen has been removed from his position as Vice President of the Chinese Academy of Engineering, though the reasons for this decision remain unclear [3] - Wang Chen is a prominent expert in respiratory medicine and has been involved in significant medical projects that have previously sparked controversy [3] Group 4 - Zhang Jianhui, the General Manager of Jindike, has passed away due to illness, marking a significant loss for the company and highlighting the risks associated with reliance on key individuals in the biotech sector [4] Group 5 - Qianhong Pharmaceutical received a regulatory letter due to its actual controller's failure to comply with disclosure obligations after increasing shareholding through block trading [5] - The increase in shareholding from 24.91% to 25.66% by the actual controller's concerted action partner indicates potential internal control issues within the company [5]